MiMedx Group financials
$4.67−0.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.4M | $59.0M | $118.1M | $113.7M | $98.6M | $88.2M | $92.9M | $84.1M | $87.2M | $84.7M | $86.8M | $81.7M |
| Gross profit | $44.4M | $41.6M | $99.0M | $95.0M | $79.9M | $71.6M | $76.0M | $68.7M | $72.4M | $71.7M | $73.0M | $66.9M |
| Gross margin | 69.0% | 70.6% | 83.9% | 83.5% | 81.1% | 81.2% | 81.8% | 81.8% | 83.0% | 84.7% | 84.1% | 81.9% |
| Operating income | -$18.5M | -$16.0M | $21.1M | $22.2M | $12.4M | $8.3M | $11.5M | $11.2M | $23.4M | $13.2M | $15.5M | $11.1M |
| Net income | -$14.8M | -$10.9M | $15.2M | $16.7M | $9.6M | $7.0M | $7.4M | $8.1M | $17.6M | $9.3M | $53.5M | $8.5M |
| Net margin | −23.1% | −18.4% | 12.9% | 14.7% | 9.8% | 8.0% | 8.0% | 9.6% | 20.2% | 10.9% | 61.6% | 10.4% |
| Diluted EPS | $-0.10 | $0.00 | $0.10 | $0.11 | $0.06 | $0.00 | $0.05 | $0.05 | $0.12 | $0.06 | $0.31 | $0.06 |
| EBITDA | -$16.9M | -$14.4M | $24.3M | $27.5M | $15.5M | $11.5M | $14.1M | $12.6M | $24.6M | $14.0M | $15.5M | $12.0M |
| Operating cash flow | -$10.0M | $1.9M | $25.0M | $29.3M | $14.4M | $5.3M | $18.8M | $19.6M | $21.8M | $6.0M | $10.3M | $12.8M |
| Free cash flow | -$10.6M | $1.3M | $24.7M | $29.1M | $14.2M | $4.9M | $18.5M | $19.5M | $21.7M | $4.8M | $9.8M | $12.2M |
| Diluted shares | 147.8M | 148.4M | 150.2M | 149.7M | 149.3M | 149.7M | 148.9M | 148.4M | 148.9M | 150.0M | 172.8M | 149.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $135.8M | $159.8M | $166.1M | $142.1M | $118.9M | $106.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $17.2M | $17.6M | $18.0M | $18.2M | $18.5M | $18.7M |
| Total assets | $281.0M | $308.7M | $342.7M | $319.0M | $291.1M | $270.4M |
| Total liabilities | $65.0M | $65.7M | $86.1M | $80.0M | $74.5M | $67.6M |
| Shareholders' equity | $216.0M | $242.9M | $256.5M | $238.9M | $216.6M | $202.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology